GLOBAL PATIENT NEED FOR NEW MEDICAL OPTIONS FOR INFERTILTY
Infertility is a disease of the male or female reproductive system that is estimated to affect 48 million couples and 186 million individuals globally, according to the World Health Organization. In couples, the origin of infertility is associated with male factors (30%); female factors (30%); combined factors (20%), and unknown origins (20%).
Igyxos’ mission is focused on addressing the unmet need for novel medical interventions and better efficacy in the treatment of infertility.
TREATMENT LIMITATIONS CONTRIBUTE TO DISEASE BURDEN
Current treatment options for infertility include hormone therapies, fertility drugs including Follicle Stimulating Hormone (FSH), surgery, and assisted reproduction technologies. Owing to the complexity of the disease, infertility treatments often involve significant financial, physical, and psychological time commitments, which exacerbate the burden of infertility for patients. This includes adherence to onerous treatment protocols for which there is historically significant (30%) discontinuation among patients. Moreover, the unsatisfactory rate of in vitro fertilization (40-50% of births in couples treated on average four-to-five times) is compounded by the high cost of treatment.
These are among the constraining factors that are contributing to the significant need for new medical options that combine increased effectiveness with a simplified and cost-effective treatment regimen for infertility.